Marksans Pharma announces UK MHRA approval for Fluoxetine 20mg/5ml oral solution

Last edition

Home › News › Drug Discovery & Development

Marksans Pharma announces UK MHRA approval for Fluoxetine 20mg/5ml oral solution

Marksans Pharma announced that UK MHRA has granted Market Authorisation to the company's wholly-owned subsidiary Relonchem Limited for Fluoxetine 20mg/5ml Oral Solution.

The therapeutic use of the product is for the treatment of depressive illness and other mental/mood disorders

The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) located at Gifford House, Slaidburn Crescent, Southport, UK.

Read more on:
Marksans Pharma UK MHRA

More news about: drug discovery & development | Published by Sudeep Soparkar | January - 24 - 2023 | 415

Last news about this category

Innocan Pharma Secures its First Patent in India for its Liposomal CBD Injection

Glenmark Pharmaceuticals Inc., USA Launches Clindamycin Phosphate Foam, 1 percent

Hoth Therapeutics Collaborates with OnTargetx R&D Inc. to Advance Research for its Cancer-Fighting Therapeutic 'HT-KIT'

Cosmo and Glenmark Receive UK MHRA Approval of Winlevi for Treatment of Acne

Jupiter Neurosciences Signs JOTROL Manufacturing Agreement with Catalent

Akums Combines Two Potent Diabetes Medicines for Enhanced Treatment Efficacy

Kenox Pharmaceuticals Enhances Capabilities to Boost Drug Development

FDA Grants Priority Review to Merck's Application for 'WELIREG'

Glenmark Pharmaceuticals Unveils Generic Anticoagulant Injectable Emulsion

Catalyst Pharmaceuticals Announces Launch of FIRDAPSE in Japan by DyDo

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy